No connection

Search Results

ARVN vs SPRY

ARVN
Arvinas, Inc.
BEARISH
Price
$12.18
Market Cap
$782.3M
Sector
Healthcare
AI Confidence
85%
SPRY
ARS Pharmaceuticals, Inc.
BEARISH
Price
$8.18
Market Cap
$812.3M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ARVN
--
SPRY
--
Forward P/E
ARVN
-3.49
SPRY
-10.8
P/B Ratio
ARVN
1.78
SPRY
7.11
P/S Ratio
ARVN
2.98
SPRY
9.64
EV/EBITDA
ARVN
-0.92
SPRY
-4.13

Profitability

Gross Margin
ARVN
100.0%
SPRY
60.13%
Operating Margin
ARVN
-754.74%
SPRY
-147.63%
Profit Margin
ARVN
-30.77%
SPRY
-203.25%
ROE
ARVN
-16.23%
SPRY
-92.33%
ROA
ARVN
-7.94%
SPRY
-33.05%

Growth

Revenue Growth
ARVN
-84.0%
SPRY
-67.6%
Earnings Growth
ARVN
--
SPRY
--

Financial Health

Debt/Equity
ARVN
0.02
SPRY
1.47
Current Ratio
ARVN
4.92
SPRY
7.28
Quick Ratio
ARVN
4.86
SPRY
6.93

Dividends

Dividend Yield
ARVN
--
SPRY
--
Payout Ratio
ARVN
0.0%
SPRY
0.0%

AI Verdict

ARVN BEARISH

ARVN's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score suggests no solvency validation. Despite a strong gross margin of 100.00%, the company reports a -30.77% profit margin, -754.74% operating margin, and an 84% YoY revenue decline, signaling fundamental business deterioration. Insider selling activity totaling $0.83M over six months, with multiple officer and CEO sales, reinforces bearish sentiment. While the stock has rebounded 42.5% over the past year, this is likely driven by speculative momentum rather than fundamentals, and the current price of $12.18 remains elevated relative to its deteriorating performance.

Strengths
Gross margin of 100.00% indicates potential product pricing power or low production costs
Extremely low debt/equity ratio of 0.02 suggests minimal financial leverage risk
High current and quick ratios (4.92 and 4.86) reflect strong short-term liquidity
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
84% YoY revenue decline and negative operating margin (-754.74%) indicate business contraction and unsustainable operations
Insider selling of $0.83M in the last 6 months, including CEO and officer sales, signals loss of confidence
SPRY BEARISH

SPRY exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. Despite a strong liquidity position (Current Ratio 7.28), the company is facing a catastrophic revenue collapse of -67.60% YoY and deep negative profit margins of -203.25%. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual data, which shows bearish insider selling and a 0/100 technical trend. The valuation remains speculative and disconnected from current operational performance.

Strengths
Very high current ratio (7.28) providing a short-term liquidity cushion
Strong quick ratio (6.93) indicating minimal reliance on inventory for liquidity
Positive gross margin (60.13%) suggesting a viable core product price point
Risks
Severe revenue contraction (-67.60% YoY)
Critical Piotroski F-Score (1/9) signaling fundamental weakness
Deeply negative profitability (Profit Margin -203.25%)

Compare Another Pair

ARVN vs SPRY: Head-to-Head Comparison

This page compares Arvinas, Inc. (ARVN) and ARS Pharmaceuticals, Inc. (SPRY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile